Capricor Therapeutics, Inc.
CAPR
$6.97
$0.081.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 392.15% | -43.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 392.15% | -43.05% | |||
| Cost of Revenue | 23.26% | -5.57% | |||
| Gross Profit | 64.13% | -11.87% | |||
| SG&A Expenses | 23.38% | 13.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.29% | -1.87% | |||
| Operating Income | 40.83% | -12.24% | |||
| Income Before Tax | 43.32% | -14.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 43.32% | -14.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.32% | -14.15% | |||
| EBIT | 40.83% | -12.24% | |||
| EBITDA | 42.11% | -12.59% | |||
| EPS Basic | 57.87% | -9.87% | |||
| Normalized Basic EPS | 58.56% | -9.87% | |||
| EPS Diluted | 57.87% | -9.87% | |||
| Normalized Diluted EPS | 58.56% | -9.87% | |||
| Average Basic Shares Outstanding | 34.51% | 3.92% | |||
| Average Diluted Shares Outstanding | 34.51% | 3.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||